<--- Back to Details
First PageDocument Content
Biotechnology / Prostate cancer / Prostate-specific antigen / Prostate / Cancer / Minimal residual disease / PCA3 / Prostate cancer screening / Medicine / Biomarkers / Tumor markers
Date: 2015-01-13 16:08:30
Biotechnology
Prostate cancer
Prostate-specific antigen
Prostate
Cancer
Minimal residual disease
PCA3
Prostate cancer screening
Medicine
Biomarkers
Tumor markers

ClinChem200905_Bruns-glucose

Add to Reading List

Source URL: www.aacc.org

Download Document from Source Website

File Size: 64,16 KB

Share Document on Facebook

Similar Documents

Large ElectronPositron Collider

Biotechnology, BS "DBEFNJD.BQ  5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT

DocID: 1xTqy - View Document

PDF Document

DocID: 1wroO - View Document

Building A Better Mousetrap: Patenting Biotechnology In The European Community

DocID: 1vr7C - View Document

BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod

DocID: 1vq6b - View Document

Biotechnology Consultation Agency Response Letter BNF

DocID: 1vpUZ - View Document